Author

M. S. Cragg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

B. Frendeus· 2 shared L. N. Dahal· 2 shared M. J. Glennie· 2 shared T. Inzhelevskaya· 2 shared A. Al-Shamkhani· 1 shared A. D. Duckworth· 1 shared A. L. Tutt· 1 shared A. Ljungars· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. Frendeus

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunity

P. T. Kennedy, E. L. Saulters, A. D. Duckworth, Y. J. Lim, J. F. Woolley, J. R. Slupsky, M. S. Cragg, F. J. Ward, L. N. Dahal

This study shows that soluble CTLA-4 suppresses T-cell activation and promotes tumor growth in mice, and that blocking sCTLA-4 enhances anti-tumor immunity.

bioRxiv · Jun 5, 2023 · PreprintCancer Biology

Synthetic STING agonists elicit powerful vaccine adjuvancy providing robust central memory and anti-tumour effects

L. D. Towner, L. N. Dahal, M. C. Taylor, K. L. Cox, T. Inzhelevskaya, M. Mack, S. R. Wedge, C. Richardson, M. S. Cragg, S. A. Beers

This study shows synthetic STING agonists enhance CD8+ T-cell responses, memory formation, and anti-tumour effects in mice, with implications for immunotherapy and vaccines.

bioRxiv · Jan 4, 2023 · PreprintImmunology

Role of the circadian clock "Death-Loop" in the DNA damage response underpinning cancer treatment resistance

N. M. Vainshelbaum, K. Salmina, B. I. Gerashchenko, M. Lazovska, P. Zayakin, M. S. Cragg, D. Pjanova, J. Erenpreisa

The paper investigates how the circadian clock 'death-loop' contributes to cancer treatment resistance by enabling DNA damage tolerance and telomere renewal in polyploid cancer cells.

bioRxiv · Jan 14, 2022Cancer Biology

Domain Binding and Isotype Dictate the Activity of Anti-human OX40 Antibodies

J. Griffiths, K. Hussain, H. L. Smith, T. Sanders, K. Cox, M. Semmrich, L. Martennson, J. Kim, T. Inzhelevskaya, C. Penfold, A. L. Tutt, I. Mockridge, C. H. Chan, V. English, R. R. French, , M. S. Cragg

This study evaluates how isotype and epitope of anti-human OX40 antibodies affect their therapeutic activity in tumor models.

bioRxiv · Jun 29, 2020Immunology

LILRB3 (ILT5) is a myeloid checkpoint on myeloid cells that elicits profound immununomodulation

M. Yeboah, C. Papagregoriou, D. C. Jones, H. T. C. Chan, G. Hu, J. S. McPartlan, T. Schiott, U. Mattson, C. I. Mockridge, U.-C. Tornberg, B. Hambe, A. Ljungars, M. Mattsson, I. Tews, M. J. Glennie, , A. Roghanian

This study identifies LILRB3 as a myeloid checkpoint receptor that suppresses immune responses through agonistic monoclonal antibodies, showing immunosuppressive effects in vitro and in humanized mice.

bioRxiv · Jun 4, 2020Immunology